Policies
Six AI Guidance Issued for Medical Device Software in 2023, Propelling China to be World Leader
NMPA affiliated Artificial Intelligence Medical Device Innovation Cooperation Platform summarized six AI related guidelines released in 2023. These documents are “based on the characteristics of AI medical devices, clarifying the technical review requirements, including general and key product requirements, and building a standard system to enhance China’s AI industry development and international influence in the space”, the platform says. For the list of guidelines please click HERE
Guidelines & Standards
Clinical Trial Inspection Key Points Ask Feedback
NMPA issued the “Key Points and Principles for Medical Device Clinical Trial Inspections (Draft) on November 28, 2023. Feedback needs to be submitted by December 31, 2023.
It stipulates on Conditions and Compliance, Protection of Subject Rights, Protocol, Implementation, Traceability and Reporting, and Devices Management of Clinical Trial. Among them, the Implementation is divided into three parts: Subject Screening and Enrollment, Execution of Clinical Trial Protocol, and Processing and Reporting of Safety Information. For our comprehensive review please click HERE
Four Draft Clinical Guidelines Issued in One Day
NMPA issued four draft clinical guidelines on December 11, 2023. Feedback needs to be submitted by January 2, 2024. It contains clinical regulations on intracranial thrombectomy stent, facial injection filler material, extracorporeal membrane oxygenation system, and spring coil system. Click HERE to learn more
Manufacturing & PMS
Three Imported Devices Found Defects in On-site Inspection
NMPA conducted on-site quality inspection on eleven types of medical devices and released the result on December 18, 2023. Eighteen manufacturers are found incompliance, including three overseas companies: Abbott Diagnostics, GALLINI and Nidek Medical. For the root causes please click HERE
Fast-Track Channel
Two Imported Devices Gain Innovation Approval in December
NMPA granted innovation approvals to seven devices in December 2023, for indications ranging from cardiovascular, orthopedic, immunology and urology. Among them are two imported devices: Varian’s proton therapy system, and BioNTech Diagnostics’ human breast cancer molecular subtyping detection kit. For more information please visit HERE
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://chinameddevice.com/nmpa-december-2023/
